AbbVie revenue trends
In 1H17, AbbVie (ABBV) reported revenues of around $13.5 million, compared to $12.4 million in 1H16. In 1Q17 and 2Q17, AbbVie reported revenues of around $6.5 million and $6.9 million, respectively, compared to $5.9 million and $6.5million in 1Q16 and 2Q16. Humira and Imbruvica primarily pushed revenue growth in 1H17.
In 1H17, AbbVie reported operating earnings of around $5.09 billion, compared to $4.67 billion in 1H16. In 1H17, AbbVie reported net earnings of around $3.6 billion, compared to $3.0 billion in 1H16.
The chart above shows the revenue curve for AbbVie from 1Q16 to 2Q17 and analysts’ estimates from 3Q17 to 4Q18. To learn more about AbbVie’s 2Q17 performance, see How Did AbbVie Perform in 2Q17?
In 1H17, AbbVie reported basic earnings per share (or EPS) of around $2.26, compared to $1.82 million in 1H16. In 1Q17 and 2Q17, the company reported basic EPS of $1.07 and $1.20, respectively, compared to $0.83 and $0.99 in 1Q16 and 1Q17.
In 1H17, AbbVie reported total current assets of around $16.96 billion, compared to $16.19 billion in 1H16.
In 1H17, AbbVie reported its cost of products sold at around $3.1 billion, compared to $2.8 billion in 1H16. In 1H17, AbbVie reported SG&A (selling, general, and administrative) expenses and R&D (research and development) expenses of around $2.87 billion and $2.36 billion, respectively, compared to $2.82 billion and $2.07 billion in 1H16.
AbbVie’s revenue growth could boost the iShares Core S&P 500 ETF (IVV). AbbVie makes up about ~0.69% of IVV’s total portfolio holdings.